BNP Paribas Financial Markets Cuts Holdings in Qiagen (NYSE:QGEN)

BNP Paribas Financial Markets lowered its holdings in Qiagen (NYSE:QGEN) by 16.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,112,202 shares of the company’s stock after selling 406,410 shares during the quarter. BNP Paribas Financial Markets’ holdings in Qiagen were worth $96,253,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. GAMMA Investing LLC increased its holdings in Qiagen by 806.5% in the 3rd quarter. GAMMA Investing LLC now owns 562 shares of the company’s stock worth $26,000 after buying an additional 500 shares in the last quarter. Toronto Dominion Bank purchased a new position in shares of Qiagen during the second quarter valued at approximately $27,000. Massmutual Trust Co. FSB ADV lifted its position in Qiagen by 39.8% during the third quarter. Massmutual Trust Co. FSB ADV now owns 853 shares of the company’s stock valued at $39,000 after purchasing an additional 243 shares during the period. CWM LLC boosted its holdings in Qiagen by 12.0% in the second quarter. CWM LLC now owns 2,505 shares of the company’s stock worth $103,000 after purchasing an additional 269 shares during the last quarter. Finally, Headlands Technologies LLC grew its position in Qiagen by 396.6% in the 2nd quarter. Headlands Technologies LLC now owns 2,741 shares of the company’s stock worth $113,000 after purchasing an additional 2,189 shares during the period. 70.00% of the stock is owned by institutional investors.

Qiagen Stock Up 0.0 %

NYSE QGEN opened at $43.26 on Wednesday. The stock’s 50-day moving average price is $43.37 and its 200-day moving average price is $43.73. The company has a market capitalization of $9.87 billion, a P/E ratio of 110.92, a price-to-earnings-growth ratio of 3.35 and a beta of 0.41. The company has a quick ratio of 1.89, a current ratio of 2.17 and a debt-to-equity ratio of 0.39. Qiagen has a 52 week low of $39.03 and a 52 week high of $47.44.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. Robert W. Baird increased their price target on Qiagen from $49.00 to $52.00 and gave the company an “outperform” rating in a report on Friday, August 2nd. Hsbc Global Res raised Qiagen to a “hold” rating in a research report on Thursday, October 17th. Finally, HSBC downgraded Qiagen from a “buy” rating to a “hold” rating and set a $49.00 price target for the company. in a research note on Thursday, October 17th. Four research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $50.88.

Qiagen Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.